rEVolutionizing Acellular Therapies with Corning HYPER Technology

This webcast features: Amy C. Kauffman, PhD, Senior Development Engineer, Corning Life Sciences

Extracellular vesicles (EVs) are a population of particles that are naturally released from cells. They are involved in intercellular communication, providing the necessary factors to mediate physiological events, and they are of high interest because of their potential for becoming the next generation of therapeutics.

One potential area of interest is in generating an EV therapeutic in place of mesenchymal stem cell (MSC) therapies for pathological conditions such as stroke, spinal cord injury, and Alzheimer’s. However, EVs pose many technical challenges in translation from bench to bedside which include lack of bioprocessing methods for scale-up of MSC-derived EVs and translation of appropriate in vitro cell culture conditions to support the intrinsic ability of MSCs to secrete the relevant variety of therapeutic molecules in high quantity into the EVs.

This presentation will share the results of our study of the effects of altering culture conditions and subsequent production of EVs produced from cells grown in the Corning HYPERStack cell culture vessel. This proof-of-concept work is a stepping-stone in exploring Corning bioproduction vessels for enhanced large-scale EV production and a future of possibilities for acellular therapies.

Key Takeaways:

  • Understand the purpose and relevance of extracellular vesicles
  • Elucidate the challenges of large-scale extracellular vesicle production
  • Learn about Corning HYPERStack technology for acellular therapy workflows

Just fill out the form below to watch the recorded webcast now.